Effects of different surfactant preparations on bacterial growth in vitro

Neonatology

Volumn 70, Issue 2, 1996, Pages 128-134

  Neumeister, B ^a   Woerndle, S ^b   Bartmann, P ^b  

^a Abteilung Medizinische Mikrobiologie und Hygiene   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Pulmonary infections; Pulmonary surfactant; Surfactant replacement therapy; Surfactant bacteria interactions

Indexed keywords

LUNG SURFACTANT; SURFACTANT;

ARTICLE; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; LEGIONELLA PNEUMOPHILA; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE;

ADULT; BACTERIA; BIOLOGICAL PRODUCTS; CELL DIVISION; DRUG COMBINATIONS; FATTY ALCOHOLS; HUMANS; INFANT; LIPIDS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; POLYETHYLENE GLYCOLS; PULMONARY SURFACTANTS; TRACHEA;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; LEGIONELLA; LEGIONELLA PNEUMOPHILA SEROGROUP 1; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B';

EID: 0029778122     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000244357     Document Type: Article

References (45)

1. Pison U, Max M, Ncucndank A, Wcissbach S, Pietschmann S: Host defence capacities of pulmonary' surfactant: Evidence for ‘non-surfactant’ functions of the surface system, EurJ Clin Invest 1994:24:586-599.
2. Griese M: I, ungensurfactant und Immunsystem, Monatsschr Kinder-heilkd 1992;140:57-61.
3. Coonrod JD, Yoneda K: Detection and partial characterization of antibacterial factors in alveolar lining material of rats, J Clin Invest 1983; 71:129-141.
4. Brogden KA: Ovine pulmonary surfactant induces killing of Pasteu-rella haemolytica, Escherichia coli, and Klebsiella pneumoniae by normal serum, Infect Immun 1992:60: 5182-5189.
5. Schwartz LW, Christman CA: Alveolar macrophage migration: Influence of lung lining material and acute lung insult, Am Rev Rcspir Dis 1979:120:429-439.
6. Hoffman RM, Claypool WD, Ka-tyal SL, Singh G, Rogers RM, Dauber JH: Augmentation of rat alveolar macrophage migration by surfactant protein, Am Rev Respir Dis 1987;135:1358-1362.
7. Wright JR, Youmans DC: Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophages, Am J Physiol 1993.264: L338-L344.
8. O’Neill SJ, Lespcrance E, Klass DJ: Rat lung surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages, Am Rev Respir Dis 1984;130:225-230.
9. O’Neill SJ, Lesperance E, Klass DJ: Human lung lavage surfactant enhances staphylococcal phagocytosis by alveolar macrophages, Am Rev Rcspir Dis 1984; 130:1177-1179.
10. Van Iwaarden F, Welmers B, Ver-hoef J, Haagsman P, Van Goldc LMG: Pulmonary surfactant protein A enhances the host defence mechanism of rat alveolar macrophages, Am J Resp Cell Mol Biol 1990:2:91-98.
11. McNcely TB, Coonrod JD: Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages, J Infect Dis 1993;167:91-97.
12. Manz-Keinke H, Plattner H, Schlcp-per-Schafer J: Lung surfactant protein A (SP-A) enhances serum-independent phagocytosis of bacteria by alveolar macrophages, Eur J Cell Biol 1992;57:95-100.
13. Geertsma MF, Nibbering PH, Haagsman HP, Daha MR, van Furth R: Binding of surfactant protein A to Clq receptors mediates phagocytosis of Staphylococcus aureus by monocytes, Am J Physiol 1994;267:L578-L584.
14. Weissbach S, Ncucndank A, Petter-son M, Schaberg T, Pison U: Surfactant protein A (SP-A) stimulates phagocytosis of Candida tropicalis by alveolar macrophages, FASEB J 1992;6:A1270.
15. Speer CP, Gotze B, Curstedt T, Robertson B: Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf), Pediatr Res 1991;30:69-74.
16. Speer CP, Gotze B, Robertson B, Curstedt T: Einfluss von natiirli-chem porcinen Surfactant (Curosurf) auf die Funktion neutrophiler Granulozyten, Monatsschr Kinder-heilkd 1990;138:737-741.
17. Geertsma MF, Broos HR, van den Barselaar MT, Nibbering PH, van Furth R: Lung surfactant suppresses oxygen-dependent bactericidal functions of human blood monocytes by inhibiting the assembly of the NADPH oxidase, J Immunol 1993;150:2391-2400.
18. Kuan SF, Rust K, Crouch E: Interactions of surfactant protein D with bacterial lipopolysaccharides, J Clin Invest 1992;90:97-106.
19. Lim BL, Wang JY, Holmskov U, Hoppe HJ, Reid KB: Expression of the carbohydrate recognition domain of lung surfactant protein D and demonstration of its binding to lipopolysaccharides of gram-negative bacteria, Biochem Biophys Res Commun 1994;202:1674-1680.
20. Van Iwaarden JF, PikaarJC, Storm J, Brouwer E, Verhocf I, Oosting RS, vam Golde LM, van Strijp JA: Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysac-charides, Biochem J 1994:303:407-411.
21. Kalina M, Blau H, Riklis S, Kratsov V: Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions, Am J Physiol 1995;268:L144-L151.
22. Thomassen MJ, Meeker PJ, Antal JM, Connors MJ, Wiedemann HP: Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages, Am J Respir Cell Mol Biol 1992;7:257-260.
23. Jarstrand C, Wiernik A, Curstcdt T, Sundquist KG: Lung surfactant inhibits the lipopolysaccharide induced release of oxygen radicals, enzymes and interleukin-1 from phagocytes, Immun Infect Dis 1991: 1:179-182.
24. Oldham KT, Guice KS, Stetson PS, Wolfe RR: Bactcremia-induced suppression of alveolar surfactant production, J Surg Res 1989:47:397-402.
25. Brodgen KA: Changes in Pulmonary Surfactant during Bacterial Pneumonia, Antonie van Leeuwenhoek, 1991. vol 59. pp 215-223.
26. Holm BA, Keicher L, Liu MY, So-kolowski J, Enhoming G: Inhibition of pulmonary surfactant function by phospholipases, J Appl Physiol 1991:71:317-321.
27. Baine WB: A phospholipasc C from the Dallas IE strain of Legionella pneumophila serogroup 5: Purification and characterization of conditions for optimal activity with an artifical substrate, J Gen Microbiol 1988:134:489-498.
28. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L: Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoal-veolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol, J Clin Invest 1982;70:673-683.
29. Holm BA, Matalon S: Role of pulmonary surfactant on the development and treatment of adult respiratory distress syndrome, Anaesth Analg 1989;69:805-818.
30. Hjalmarson O: Epidemiology and classification of acute neonatal respiratory disorders, Acta Pacdiatr Scand 1981;70:773-781.
31. Collaborative European Multicenter Study Group: Surfactant replacement therapy for severe neonatal respiratory distress syndrome: An international randomized clinical trial, Pediatrics 1988;82:683-691.
32. Cortner L, Pohlandt F, Bartmann P: Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: A multicenter controlled clinical trial, Pediatr Pulmol 1992;14:4-9.
33. Brehmer U, Jorch G: Surfactant-therapie bei schwerer neonatalcr Ateminsuffizienz - Multizertrischc Studie, III, Surfactanttherapie bei 41 Friihgeborcncn 34 SSW mit Verdacht auf konnatale Infektion (Fallkontrollanalysc), Klin Padiatr 1993;205:8-12.
34. Auten RL, Nottcr RH, Kendig JW, Davis JM, Shapiro DL: Surfactant treatment of full-term newborns with respiratory failure, Pediatrics 1991;87:101-107.
35. Lotze A, Knight GR, Martin GR, Bulas DL Hull WM, O'Donnell RM, Whitsett JA, Short BL: Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring ex-tracorporeal membrane oxygenation, J Pediatr 1993;122:261-268.
36. LaForcc FM, Boose DS: Sublethal damage of Escherichia coli by lung lavage, Am Rev Respir Dis 1981; 124:733-737.
37. LaForcc FM, Boose DS: Effect of zinc and phosphate on an antibacterial peptide isolated from lung lavage, Infect Immun 1984;45:692-696.
38. Lehrer RL Selstcd ME, Szklarek D, Fleischmann J: Antibacterial activity of microbicidal cationic proteins 1 and 2. natural peptide antibiotics of rabbit lung macrophages, Infect Immun 1983;42:10-14.
39. MacDonald JT, Maheswaran SK, Opuda-Asibo J, Townsend EL, Thics ES: Susceptibility of Pasteu-rella haemolytica to the bactericidal effects of serum, nasal secretions and bronchoalveolar washings from cattle, Vet Sci 1983;8:585-599.
40. LaForcc FM, Kelly WJ, Huber GL: Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material, Am Rev Respir Dis 1973;108:784-790.
41. Juers JA, Rogers RM, McCurdy JB, Cook WW: Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material, J Clin Invest 1976;58: 271-275.
42. Jonsson S, Musher DM, Gorcc A, Lawrence EC: Human alveolar lining material and antibacterial defenses, Am Rev Respir Dis 1986; 133:136-140.
43. Sherman MP, Campbell LA, Merritt TA, Long WA, Gunkel JH, Curstedt T, Robertson B: Effect of three different surfactants on pulmonary' group B streptococcal infection in premature rabbits, J Pediatr 1994; 125:939-947.
44. Sherman MP, Campbell LA, Merritt TA, Shapiro DL, Long WA, Gunkel JH: The infected preterm rabbit lung; in von Wichert P, Muller B (eds): Basic Research on Lung Surfactant, Basel, Karger, 1990, pp 204-208.
45. Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B: Experimental neonatal group B streptococcal pneumonia: Effect of a modified procine surfactant on bacterial proliferation in ventilated near-term rabbits, Pediatr Res 1994: 36:784-791.